Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction‐associated steatotic liver disease

Abstract

We identified a distinctive metabolic signature in obesity marked by changes in tryptophan catabolic pathways, discernible through altered metabolite profiles. We observed stage-specific alterations in tryptophan catabolism fluxes in MASLD, highlighting the potential utility of targeting these pathways in therapeutic interventions.